Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Vaxcyte, Inc. Director's Dealing 2025

Dec 29, 2025

31100_dirs_2025-12-29_da27a3e3-0252-4ed5-aa33-08096e4c4bd6.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2025-12-23

Reporting Person: Cowan Elvia (SVP, FINANCE)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-12-23 Common Stock S 4907 $47.899 Disposed 21250 Direct
2025-12-23 Common Stock S 6716 $47.935 Disposed 14534 Direct
2025-12-23 Common Stock G 1000 Disposed 13534 Direct

Footnotes

F1: Includes one (1) share acquired on November 17, 2025 under the Issuer's Employee Stock Purchase Plan.

F2: Reflects the bona-fide gift of the Issuer's common stock to a Charitable Donor Advised Fund.